Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
50%(1 trials)

Phase Distribution

Ph not_applicable
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
N/ANon-phased studies
1(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(2)

Detailed Status

Completed2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A1 (100.0%)

Trials by Status

completed267%
recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
completed

An ACDF Multi-Center Study Using ViviGen Cellular Bone Matrix

NCT02814825
completed

ViviGen Cellular Bone Matrix for Hindfoot or Ankle Arthrodesis

NCT04138017
recruitingnot_applicable

Comparison of Radiographic Fusion Rate and Clinical Outcome of ALIF and XLIF Performed With Either Recombinant Human Bone Morphogenetic Protein-2 or ViviGen®

NCT05238740

Clinical Trials (3)

Showing 3 of 3 trials
NCT02814825

An ACDF Multi-Center Study Using ViviGen Cellular Bone Matrix

Completed
NCT04138017

ViviGen Cellular Bone Matrix for Hindfoot or Ankle Arthrodesis

Completed
NCT05238740Not Applicable

Comparison of Radiographic Fusion Rate and Clinical Outcome of ALIF and XLIF Performed With Either Recombinant Human Bone Morphogenetic Protein-2 or ViviGen®

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
3